Restoring responses to immunotherapy in metastatic lymph nodes in hnscc

Active Grant Awarded

Award ID
R01DE035887
Recipient
Awarding agency
Obligated
$684,832

Award facts

Assistance listing
93.121 Oral Diseases and Disorders Research
Completion date 3% complete
Place of performance
San Francisco, CA 94143, USA

Award details come from USAspending.gov.

About this award

The National Institute of Dental and Craniofacial Research, within the Department of Health and Human Services' National Institutes of Health, awarded The Regents of the University of California, San Francisco $684,832 on September 23, 2026, under Grant R01DE035887 in the Oral Diseases and Disorders Research program (Assistance Listing 93.121).

The funded research addresses restoring T cell responses to immune checkpoint blockade in metastatic lymph nodes in head and neck squamous cell carcinoma (HNSCC). Building on the finding that progenitor exhausted CD8 T cells (TPEX) in lymph nodes respond to checkpoint blockade but are substantially impaired in metastatic lymph nodes, the project aims to define the mechanisms of that impairment and to target them to improve immunotherapy response. The studies leverage banked biospecimens from patients with HNSCC.

The recipient is The Regents of the University of California, San Francisco, operating through its Controller's Office. Place of performance is San Francisco, California 94143. The period runs from the September 23, 2026 award date to an ultimate completion date of July 31, 2031. The source identifies no sub-recipients for this award. The program supports basic, translational, and clinical research in dental, oral, and craniofacial health and disease through grants and cooperative agreements.

Description

Abstract
Immunotherapies for cancer have the potential to drive immune responses that clear established tumors and provide long-term, durable protection against cancer recurrence through immunological memory. However, less than 20% of patients with head and neck squamous cell carcinomas (HNSCC) currently benefit from available immunotherapy, immune checkpoint blockade (ICB) targeting the inhibitory receptor PD1. As a result of the landmark keynote-689 clinical trial, ICB initiated prior to surgery (NEOADJUVANT) is a new standard of care for patients with for resectable locally advanced HNSCC. In this setting, ICB is given prior to resection of lymph nodes (LN). We recently discovered that LN are a critical site for T cell activation after ICB in patients with HNSCC. However, as noted by the nidcr, many patients with HNSCC present with regional metastases to lymph nodes (LN). We found that T cell responses to ICB are substantially impaired in metastatic (met)LN, presenting a critical barrier to effective immunotherapy. Thus, a key GAP in the field is how best to stimulate T cell responses in metln. Progenitor exhausted CD8 T cells (tpex: PD1+ TCF1+) are the critical cell population that responds to ICB in mice and humans. We recently found that tpex in LN of patients with HNSCC responded to ICB, CO-localizing with dendritic cells (DCS) and giving rise to more intermediate exhausted cells (TEX-INT) that downregulated TCF1, upregulated PD1, and proliferated after therapy. LN responses were correlated with blood and tumor responses. However, these responses were significantly impaired in metln, where tpex become surrounded by immunosuppressive niches. We designed a focused and hypothesis-driven strategy to understand the mechanisms of tpex impairment in metln and to target them to improve response to ICB. Our studies leverage [a] banked biospecimens from patients with HNSCC who enrolled in our NEOADJUVANT clinical trial, in which a dose of ICB as monotherapy or in combination is given prior to surgery, [B] our novel primary human LN organoid platform, which enables mechanistic studies of patient-derived LN, and [C] orthotopic mouse models of HNSCC. In aim 1, we will dissect key cellular interactions between tpex, DCS, and tregs in metln. Among pathways we will investigate, based on our preliminary data, we will examine the role of the tigit pathway in mice and in human tissues from a recently completed combination therapy treatment arm of our NEOADJUVANT clinical trial. In aim 2, we examine changes in tpex survival and function in metln. We recently found that activating the IL-7 pathway is a powerful strategy to drive tpex proliferation in LN and to steer their differentiation toward effector-like cells rather than terminally-exhausted cells in mice and in patients with HNSCC. We will test whether this strategy can rescue tpex persistence and function in metln. This study will comprehensively determine the mechanisms by which tpex responses to ICB are impaired in metln and rational strategies to overcome this barrier. This will advance our goal to extend the promise of immunotherapy to all cancer patients, including those with regional metastasis to LN.

Quick answers

Who received award R01DE035887?

R01DE035887 was awarded to The Regents Of The University Of California. San Francisco by National Institute of Dental and Craniofacial Research (National Institutes of Health) on September 23, 2026.

How much is award R01DE035887 worth?

$684,832 has been obligated on R01DE035887.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award